Shares of pharmaceutical firm Wanbury Ltd were trading 4% lower on Tuesday, 20 May, despite securing good manufacturing practices (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its facility in Raigad, Maharashtra.

The accreditation confirms that the company follows Brazilian GMP criteria, which are consistent with the World Health Organisation’s recommendations, according to an exchange filing.

The accreditation primarily addresses the manufacturing of metformin hydrochloride, an active pharmaceutical ingredient (API) used to treat diabetic mellitus.

Wanbury’s approved plant is located at A-15, MIDC Industrial Area, Patalganga, Raigad District, Maharashtra. The accreditation is valid until 12 May, 2027, with a caveat noting that it may be revoked if the company fails to meet current GMP criteria.

On 12 May, Wanbury announced that the company had received clearance and certification from ANVISA, Brazil, for its Tanuku location in Andhra Pradesh as well.

In September 2024, the European Directorate for the Quality of Medicines (EDQM) gave the company a certificate of appropriateness (CEP) for its active pharmaceutical ingredient (API), Dextromethorphan. This API is commonly used as an antitussive and is an important component in cough suppressant medicines.

Wanbury Ltd earned Rs 173.84 crore in Q4FY25, up from Rs 140.33 crore the previous year. The company made a net profit of Rs 20.25 crore in Q4 FY25, down from Rs 33.63 crore in the same period the previous year.

At 12 pm, Wanbury shares were trading at Rs 292.62, down 3.82%.

Stay Ahead with Wanbury Ltd. Ask the Analyst.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!